drugset / Trial / NCT04712734

A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia

NCT04712734

Phase 1 Completed 42 enrolled Vanda Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, adaptive, repeat-dose study to evaluate the safety, tolerability, and pharmacokinetics of iloperidone long-acting injection (LAI) in patients with schizophrenia.

Timeline

Start
2021-01-13
Primary completion
2022-08-30
Completion
2022-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Iloperidone Small molecule Oral

Indications